| Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Erck Stanley C | President and CEO | Oct 01 | Sale | 108.57 | 2 | 217 | 20,494 | Oct 01 05:39 PM | | Trizzino John | EVP, CBO and CFO | Sep 30 | Sale | 110.22 | 2,250 | 248,002 | 5,087 | Oct 01 05:40 PM | | Erck Stanley C | President and CEO | Sep 30 | Sale | 110.23 | 12,231 | 1,348,200 | 20,496 | Oct 01 05:39 PM | | Herrmann John A III | EVP, Chief Legal Officer | Sep 29 | Sale | 107.31 | 18,029 | 1,934,667 | 275 | Sep 30 09:30 PM | | Glenn Gregory M | President, R&D | Sep 29 | Sale | 107.02 | 19,949 | 2,134,844 | 1,561 | Sep 30 09:29 PM | | Trizzino John | EVP, CBO and CFO | Sep 29 | Sale | 107.29 | 18,321 | 1,965,630 | 7,337 | Sep 30 09:28 PM | | Erck Stanley C | President and CEO | Sep 29 | Sale | 107.80 | 4,112 | 443,267 | 32,727 | Sep 30 09:27 PM | | Erck Stanley C | President and CEO | Sep 28 | Option Exercise | 5.95 | 50,000 | 297,500 | 74,606 | Sep 30 09:27 PM | | Trizzino John | EVP, CBO and CFO | Sep 28 | Option Exercise | 5.95 | 29,600 | 176,120 | 53,008 | Sep 30 09:28 PM | | Glenn Gregory M | President, R&D | Sep 28 | Option Exercise | 5.95 | 25,000 | 148,750 | 46,510 | Sep 30 09:29 PM | | Herrmann John A III | EVP, Chief Legal Officer | Sep 28 | Option Exercise | 5.95 | 24,750 | 147,263 | 43,054 | Sep 30 09:30 PM | | Glenn Gregory M | President, R&D | Sep 28 | Sale | 110.30 | 25,000 | 2,757,456 | 21,510 | Sep 30 09:29 PM | | Trizzino John | EVP, CBO and CFO | Sep 28 | Sale | 110.30 | 25,000 | 2,757,456 | 25,658 | Sep 30 09:28 PM | | Erck Stanley C | President and CEO | Sep 28 | Sale | 110.30 | 25,000 | 2,757,456 | 36,839 | Sep 30 09:27 PM | | Herrmann John A III | EVP, Chief Legal Officer | Sep 28 | Sale | 110.30 | 24,750 | 2,729,879 | 18,304 | Sep 30 09:30 PM | | EVANS GARY C | Director | Aug 18 | Option Exercise | 31.02 | 10,500 | 325,700 | 332,479 | Aug 20 06:09 PM | | Glenn Gregory M | President, R&D | Aug 18 | Option Exercise | 33.56 | 55,921 | 1,876,525 | 57,760 | Aug 20 06:14 PM | | Herrmann John A III | EVP, Chief Legal Officer | Aug 18 | Option Exercise | 53.82 | 46,242 | 2,488,613 | 46,517 | Aug 20 06:20 PM | | MCMANUS MICHAEL A JR | Director | Aug 18 | Option Exercise | 27.60 | 8,000 | 220,800 | 17,951 | Aug 20 06:22 PM | | Trizzino John | EVP, CBO and CFO | Aug 18 | Option Exercise | 50.95 | 42,788 | 2,179,986 | 47,875 | Aug 20 06:25 PM | | Trizzino John | EVP, CBO and CFO | Aug 18 | Sale | 148.78 | 42,788 | 6,366,182 | 5,087 | Aug 20 06:25 PM | | MCMANUS MICHAEL A JR | Director | Aug 18 | Sale | 146.00 | 8,000 | 1,168,000 | 9,951 | Aug 20 06:22 PM | | Herrmann John A III | EVP, Chief Legal Officer | Aug 18 | Sale | 144.33 | 46,242 | 6,673,982 | 275 | Aug 20 06:20 PM | | Glenn Gregory M | President, R&D | Aug 18 | Sale | 145.20 | 55,921 | 8,119,860 | 1,839 | Aug 20 06:14 PM | | EVANS GARY C | Director | Aug 18 | Sale | 150.44 | 10,500 | 1,579,620 | 321,979 | Aug 20 06:09 PM | | Glenn Gregory M | President, R&D | Jun 18 | Option Exercise | 42.20 | 16,749 | 706,808 | 18,588 | Jun 22 05:29 PM | | Glenn Gregory M | President, R&D | Jun 18 | Sale | 59.53 | 16,749 | 997,103 | 1,839 | Jun 22 05:29 PM | | YOUNG JAMES F | Director | Jun 03 | Buy | 48.83 | 1,500 | 73,245 | 1,500 | Jun 05 05:04 PM | | Herrmann John A III | SVP, General Counsel | May 18 | Option Exercise | 26.19 | 12,961 | 339,448 | 7,774 | May 20 04:35 PM | | Herrmann John A III | SVP, General Counsel | May 18 | Sale | 49.44 | 12,961 | 640,792 | 275 | May 20 04:35 PM | | Glenn Gregory M | President, R&D | Jan 31 | Buy | 3.86 | 1,250 | 4,825 | 1,373 | Feb 04 05:11 PM | | MCMANUS MICHAEL A JR | Director | Nov 18 | Sale | 3.82 | 3,929 | 15,015 | 9,951 | Nov 20 04:17 PM |
|
